Epidermal SH-protease inhibitor (ACPI, cystatin A) in cancer. A short historical review.
This review article will re-report the findings from 30 years ago concerning the implications of the acid cystein proteinase inhibitor (ACPI) to the field of cancer research. The original article, published in 1980, has erroneously been omitted from electronic article databases. The findings reported in the original article suggest that some anaplastic lung cancers should be classified as epidermal. In this article we also consider the yet unknown physiological function of ACPI. Furthermore, we will address the simplification of the nomenclature of ACPI and related molecules.
Rinne
Ari
A
Department of Pathology, University of Tromsø, Tromsø, Norway.
D014408:Biomarkers, Tumor / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000378:metabolism*
D014408:Biomarkers, Tumor; D015853:Cysteine Proteinase Inhibitors